Chapter 7. Antimetabolites in Cancer Therapy

  1. Sotiris Missailidis
  1. Jessica Scaife1 and
  2. David Kerr2

Published Online: 7 NOV 2008

DOI: 10.1002/9780470697047.ch7

Anticancer Therapeutics

Anticancer Therapeutics

How to Cite

Scaife, J. and Kerr, D. (2008) Antimetabolites in Cancer Therapy, in Anticancer Therapeutics (ed S. Missailidis), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9780470697047.ch7

Editor Information

  1. Department of Chemistry and Analytical Sciences, The Open University, Milton Keynes, UK

Author Information

  1. 1

    ST2 Core Medical Training, Department of Oncology, Cheltenham General Hospital, Cheltenham, UK

  2. 2

    Department of Clinical Pharmacology, University of Oxford, Old Road Campus Research Building, Oxford, UK

Publication History

  1. Published Online: 7 NOV 2008
  2. Published Print: 21 NOV 2008

ISBN Information

Print ISBN: 9780470723036

Online ISBN: 9780470697047



  • normal biochemical reaction metabolites;
  • cancer therapy antimetabolites;
  • folate antagonists;
  • methotrexate and routine pharmacokinetic monitoring;
  • pyrimidine antagonists;
  • NICE (National Institute for Clinical Excellence) guidelines and Dukes' C carcinoma;
  • capecitabine monotherapy;
  • doxifluridine - oral prodrug;
  • antimetabolites - haematological malignancy therapeutic mainstay


This chapter contains sections titled:

  • Introduction

  • Folate Antagonists

  • Pyrimidine Antagonists

  • Purine Antagonists

  • Summary

  • References